Gland Pharma receives EIR from US FDA for Dundigal Facility at Hyderabad

04 Jan 2023 Evaluate

Gland Pharma has received the Establishment Inspection Report (EIR) from the Office of Product Evaluation and Quality Center for Devices and Radiological Health, US FDA indicating closure of the inspection at Dundigal Facility in Hyderabad. Earlier, the Pre-Market Inspection covering US FDA’s Quality System/Current Good Manufacturing Practice regulations for Medical Devices (21 CFR Part 820) at the company’s Dundigal Facility at Hyderabad was conducted from  August 22, 2022 to  August 25, 2022. The company had received 1 observation on Form 483 with respect to ANDA filed for the product to be manufactured at the said Facility.

Gland Pharma develops, manufactures and markets complex injectables. The company sells its products primarily under a business-to-business model in many countries.

Gland Pharma Share Price

1851.00 11.85 (0.64%)
03-Jun-2024 14:51 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1460.70
Dr. Reddys Lab 5790.25
Cipla 1449.85
Zydus Lifesciences 1033.50
Lupin 1583.20
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.